A Clinical Experience on Sulodexide in the Treatment of Patients with Diabetic Nephropathy

Abstract

Background: Diabetic nephropathy, characterized by albuminuria, is a severe complication of diabetes mellitus, leading cause of end-stage renal disease. The aim of the present study was to evaluate the efficacy and safety of sulodexide, alone or in combination with captopril, versus captopril alone in consecutive adult patients with diabetic nephropathy.

Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis

“…Blinding, with appropriate masking when needed, was specifically indicated in 11 studies [ 64 , 68 – 70 , 75 , 80 , 89 , 92 , 97 , 99 , 102 ]. Another 13 studies were explicitly defined or implicitly detected as open-label [ 63 , 71 , 72 , 74 , 90 , 91 , 94 – 96 , 98 , 100 , 101 , 104 ]. The risk of selection of the reported results was due in some cases to the open-label design, but mostly to the absence of sufficient details on the protocol, so that it was impossible to understand whether the data had been analyzed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis.…”

“…The studies on diabetic nephropathy described essentially the same phenomenon: change in albuminuria, but measured and reported with different techniques, namely arithmetic mean (reported or derived [ 52 ]) as micrograms per minute or milligrams per day or milligrams per 24 h or micrograms per milligram creatinine [ 45 , 73 – 78 , 80 – 83 , 85 – 88 , 91 , 94 , 96 , 98 , 101 – 103 , 105 ], geometric mean [ 79 , 84 , 89 , 95 , 100 ], geometric mean of percentage change [ 90 , 93 , 104 ], rate of change in micrograms per milligram per year [ 99 ], or therapeutic success defined in different ways [ 92 , 97 ]. Geometric means, reported with the asymmetric 95% CI, had to be logarithmically transformed to estimate the symmetric standard deviation.…”